Athira Pharma, Inc.'s (NASDAQ:ATHA) 81% Loss Last Week Hit Both Individual Investors Who Own 38% as Well as Institutions
Athira Plunges as Alzheimer's Trial Setback Leads to Downgrades
Athira Pharma ATHA Phase 2/3 Data; Oragenics OGEN Offering
Top Midday Decliners
Mizuho Securities Maintains Athira(ATHA.US) With Buy Rating, Announces Target Price $5
Mizuho Securities analyst Graig Suvannavejh maintains $Athira(ATHA.US)$ with a buy rating, and sets the target price at $5.According to TipRanks data, the analyst has a success rate of 44.9% and a
JMP Securities Downgrades Athira Pharma to Market Perform